N/A N=30 Home Usability Study of the SARS-CoV-2 (COVID-19) Test
COVID-19
Primary: Valid SARS-CoV-2 Test — 30 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=12 Smith-Lemli-Opitz Syndrome and Cholic Acid
Smith-Lemli-Opitz Syndrome
Primary: Change in Plasma Cholesterol — 37.8 change (%) compared to baseline — p=0.011
Phase 3 N=1,213 Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma
Urothelial Carcinoma
Primary: Investigator Assessed Progression-Free Survival (PFS) in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm…
Phase 2 N=124 Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild-Moderate COVID-19 Hospitalized Patients
Covid-19
Primary: Recover Ratio — 47; 48; 1; 0 Participants
Phase 2 N=10 Phase 2 Study of Obeticholic Acid for Lipodystrophy Patients
Familial Partial Lipodystrophy
Primary: Change in the Liver Triglycerides (TG). — 13.2; 6.4; 12.3; 10.6 percentage of liver triglycerides
Phase 2 N=50 Ad26.ZEBOV Booster in Children Previously Vaccinated With Ad26.ZEBOV and MVA-BN-Filo (EBOVAC Booster Study)
Ebola Virus Disease
Primary: Number of Participants With Solicited Local (at the Administration Site) Adverse Events — 18 Participants
N/A N=1,135 Protocol-guided Rapid Evaluation of Veterans Experiencing New Transient Neurological Symptoms
Transient Ischemic Attack · Stroke
Primary: Effectiveness: Without-fail Care Rate — 95; 363 Participants
Phase 2 N=5 A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)
Transfusion Dependent Beta-thalassemia
Primary: Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 156 Weeks After the ST-400 Infusion — 5; 2 participants
N/A N=421 Pulsed Field Ablation to Irreversibly Electroporate Tissue and Treat AF
Atrial Fibrillation
Primary: Safety: Number of Participants With at Least One Primary Safety Event — 1; 1 Participants
Phase 2 N=28 Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC)
Advanced Non-small Cell Lung Cancer
Primary: Best Overall Response (BOR) — 2; 2; 9; 1 Participants
Phase 2 N=5 68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer
Breast Carcinoma · Estrogen Receptor Positive
Primary: Detection of ER Positive Breast Cancer and Metastases on 68-Ga RM2 PET/MRI — 4; 1 Participants
N/A N=65 A Novel fNIRS Neurofeedback Intervention for Enhancement of Working Memory in Attention Deficit Hyperactivity Disorder (ADHD)
ADHD
Primary: Change in Target Frontal-parietal Activity — 2.31; -4.74 beta coefficient
Phase 2 N=44 Tolerability, Safety, and Efficacy of Tedizolid as Oral Treatment for Bone and Joint Infections (OTTER)
Bone and Joint Infection
Primary: Quantify the Tolerability of Tedizolid for Bone and Joint Infections, Both Hardware and Non-hardware Associated — 0; 0 participants
N/A N=6 New Skills - No Scores Research Study
Intellectual Disability
Primary: Motivation and Confidence in Physical Activity — 3.42; 3.42; 3.17; 3.42 score on a scale
N/A N=65 CTSI Pilot: Improving Adherence to Diabetic Diet
Diabetes Mellitus, Type 2 · Diet, Healthy · Pre-diabetes
Primary: Calories Purchased — 24443.30; 25339.20; 18527.35 Kcal